作为具有抗癌潜力的双COX-2/EGFR抑制剂的皮拉衍生物:对二胺醇类型的优化
Kawther O Farag1, Mai S Nour1, Mai M Abdelhafez2
1Pharmaceutical Chemistry Department, Faculty of Pharmacy, October University of Modern Sciences and Arts (MSA), 6th of October City, Giza, Egypt.
Bioorganic chemistry
|January 8, 2026
概括
针对COX-2和EGFR的新型药物化合物显示出治疗多种质母细胞瘤 (GBM) 的前景. 化合物10a表现出强大的双抑制和显著的GBM细胞毒性,特别是针对SNB-75细胞系.
科学领域:
- 药用化学 医学化学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 多形质母细胞瘤 (GBM) 表现出循环氧化酶-2 (COX-2) 和表皮生长因子受体 (EGFR) 的过度表达,具有关键的治疗点.
- 双胺醇是一种可穿透血脑屏障的COX抑制剂,作为设计新型类似物的支架.
研究的目的:
- 设计和合成具有增强COX-2选择性和引入EGFR抑制活性的新型Difenamizole类似物.
- 评估合成化合物的 analgesic,COX 抑制,EGFR 抑制和质母细胞瘤细胞毒性作用.
主要方法:
- 用修改后的N替代剂合成新的Difenamizole类似物.
- 在体外测试以确定镇痛作用 (AUC值),COX-1/COX-2抑制 (IC50,SI值),EGFR抑制 (IC50) 和针对GBM细胞系的细胞毒性 (U-251,SNB-75).
主要成果:
- 几种衍生品表现出强烈的止痛作用,与塞莱科克西布相当.
- 化合物8d和10a显示出显著的COX-2抑制,对COX-1具有很高的选择性.
- 化合物10a对U-251和SNB-75 GBM细胞表现出强大的EGFR抑制和显著的细胞毒性,在SNB-75对抗Staurosporine和NS-398方面表现优于Staurosporine和NS-398.
结论:
- 化合物10a成为GBM的有希望的双重向治疗候选者,有效抑制COX-2和EGFR.
- 这些发现突出了化合物10a的独特特征,它结合了高的COX-2选择性,EGFR抑制和强大的GBM细胞毒性,特别针对SNB-75细胞系.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
801
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
801
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
564
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
564
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
594
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
594


